LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE
Clinical trials for LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE explained in plain language.
Never miss a new study
Get alerted when new LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE trials appear
Sign up with your email to follow new studies for LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Personalizing leukemia drug doses could boost treatment success
Disease control CompletedThis trial investigates whether adjusting the dose of imatinib (Gleevec) based on the drug's level in the blood can improve outcomes for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). Participants whose imatinib blood level is low after 28 days are rand…
Matched conditions: LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE
Phase: PHASE2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can a second-line drug help CML patients stay cancer-free without daily pills?
Disease control CompletedThis study looked at 31 adults with chronic myeloid leukemia (CML) whose cancer came back after they stopped taking imatinib. They were given nilotinib, a more powerful targeted therapy, to see if it could make their cancer undetectable again and allow them to stop treatment once…
Matched conditions: LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC